ghk-cu fda approved drug The FDA is reviewing 12

Mitochondrial Respiration and Hypoxia Protection The 2003 study by Khvatova, Samartzev, Zagoskin, Prudchenko, and Mikhaleva published in Peptides confirmed that DSIP significantly increased ADP-stimulated mitochondrial respiration in rat brain mitochondria under experimental hypoxia conditions establishing a direct mitochondrial respiratory mechanism for DSIPs stress-protective potency and linking DSIP biology to the emerging field of mitochondria-targeted neuroprotective peptides

It is not intended for diagnostic, therapeutic, or clinical implementation

However, like all research peptides, it must be used only in non-human laboratory settings , and should never be promoted or interpreted as a therapeutic product

The unique combination of lipotropic agents in our injections aids in breaking down fat, transporting it, and assisting in its removal from the body

while normal dietary intake is considered safe, the effects of high-dose parenteral administration are less well studied

it is precautionary convention